BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 20044629)

  • 1. Statins and breast cancer in postmenopausal women without hormone therapy.
    Eaton M; Eklof J; Beal JR; Sahmoun AE
    Anticancer Res; 2009 Dec; 29(12):5143-8. PubMed ID: 20044629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for hormone receptor-defined breast cancer in postmenopausal women.
    Rosenberg LU; Einarsdóttir K; Friman EI; Wedrén S; Dickman PW; Hall P; Magnusson C
    Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2482-8. PubMed ID: 17164374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association between 3-hydroxy-3-methylglutaryl conenzyme A inhibitor use and breast carcinoma risk among postmenopausal women: a case-control study.
    Boudreau DM; Gardner JS; Malone KE; Heckbert SR; Blough DK; Daling JR
    Cancer; 2004 Jun; 100(11):2308-16. PubMed ID: 15160333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users.
    Kumar AS; Benz CC; Shim V; Minami CA; Moore DH; Esserman LJ
    Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1028-33. PubMed ID: 18463402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Body size, physical activity, and breast cancer hormone receptor status: results from two case-control studies.
    Enger SM; Ross RK; Paganini-Hill A; Carpenter CL; Bernstein L
    Cancer Epidemiol Biomarkers Prev; 2000 Jul; 9(7):681-7. PubMed ID: 10919738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of regimens of hormone replacement therapy to prognostic factors among women diagnosed with breast cancer aged 50-64 years.
    Daling JR; Malone KE; Doody DR; Voigt LF; Bernstein L; Marchbanks PA; Coates RJ; Norman SA; Weiss LK; Ursin G; Burkman RT; Deapen D; Folger SG; McDonald JA; Simon MS; Strom BL; Spirtas R
    Cancer Epidemiol Biomarkers Prev; 2003 Nov; 12(11 Pt 1):1175-81. PubMed ID: 14652277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions between body mass index and hormone therapy and postmenopausal breast cancer risk (United States).
    Li CI; Malone KE; Daling JR
    Cancer Causes Control; 2006 Jun; 17(5):695-703. PubMed ID: 16633917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women.
    Missmer SA; Eliassen AH; Barbieri RL; Hankinson SE
    J Natl Cancer Inst; 2004 Dec; 96(24):1856-65. PubMed ID: 15601642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unopposed estrogen therapy and the risk of invasive breast cancer.
    Chen WY; Manson JE; Hankinson SE; Rosner B; Holmes MD; Willett WC; Colditz GA
    Arch Intern Med; 2006 May; 166(9):1027-32. PubMed ID: 16682578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated levels of circulating insulin-like growth factor-I, IGF-binding globulin-3 and testosterone predict hormone-dependent breast cancer in postmenopausal women: a case-control study.
    Kahán Z; Gardi J; Nyári T; Földesi I; Hajnal-Papp R; Ormándi K; Lázár G; Thurzó L; Schally AV
    Int J Oncol; 2006 Jul; 29(1):193-200. PubMed ID: 16773200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alcohol and breast cancer risk defined by estrogen and progesterone receptor status: a case-control study.
    Deandrea S; Talamini R; Foschi R; Montella M; Dal Maso L; Falcini F; La Vecchia C; Franceschi S; Negri E
    Cancer Epidemiol Biomarkers Prev; 2008 Aug; 17(8):2025-8. PubMed ID: 18708394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones.
    Tworoger SS; Missmer SA; Barbieri RL; Willett WC; Colditz GA; Hankinson SE
    J Natl Cancer Inst; 2005 Apr; 97(8):595-602. PubMed ID: 15840882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma.
    Chen WY; Hankinson SE; Schnitt SJ; Rosner BA; Holmes MD; Colditz GA
    Cancer; 2004 Oct; 101(7):1490-500. PubMed ID: 15378477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
    Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
    Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormone replacement therapy use and variations in the risk of breast cancer.
    Opatrny L; Dell'Aniello S; Assouline S; Suissa S
    BJOG; 2008 Jan; 115(2):169-75; discussion 175. PubMed ID: 18081598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Menopausal hormone therapy and breast cancer phenotype: does dose matter?
    Garwood ER; Kumar AS; Shim V
    Ann Surg Oncol; 2008 Sep; 15(9):2526-32. PubMed ID: 18618187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
    Winer EP; Hudis C; Burstein HJ; Wolff AC; Pritchard KI; Ingle JN; Chlebowski RT; Gelber R; Edge SB; Gralow J; Cobleigh MA; Mamounas EP; Goldstein LJ; Whelan TJ; Powles TJ; Bryant J; Perkins C; Perotti J; Braun S; Langer AS; Browman GP; Somerfield MR
    J Clin Oncol; 2005 Jan; 23(3):619-29. PubMed ID: 15545664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of serum estrone levels with estrogen receptor-positive breast cancer risk in postmenopausal Japanese women.
    Miyoshi Y; Tanji Y; Taguchi T; Tamaki Y; Noguchi S
    Clin Cancer Res; 2003 Jun; 9(6):2229-33. PubMed ID: 12796390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
    Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE
    J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum calcium levels are elevated among women with untreated postmenopausal breast cancer.
    Martin E; Miller M; Krebsbach L; Beal JR; Schwartz GG; Sahmoun AE
    Cancer Causes Control; 2010 Feb; 21(2):251-7. PubMed ID: 19856117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.